Lipo-MIC + NAD+

Lipo-MIC + NAD+ is a compounded lipotropic injectable that joins the traditional MIC nutrients, methionine, inositol, and choline, with nicotinamide adenine dinucleotide (NAD+) or its precursors ^[1][3]. The MIC portion follows the long-standing lipotropic concept of supplying methyl donors and related cofactors that support the liver's handling of fat, while the NAD+ portion addresses cellular energy metabolism and is a more recent addition associated with the longevity and metabolic-health field.

Choline and methionine are essential contributors to hepatic lipid export; human and animal data show that inadequate choline leads to fat accumulation and liver dysfunction, and choline metabolism is closely tied to the development and progression of nonalcoholic fatty liver disease ^[1]. Methionine-and-choline-deficient models reliably generate hepatic steatosis, illustrating the nutrients' role in moving fat out of the liver ^[2]. NAD+ is a coenzyme required for hundreds of oxidation-reduction reactions in energy production and is the substrate for sirtuins and other enzymes that regulate metabolism; because tissue NAD+ tends to decline with age, raising its availability has become a focus of research ^[3][4].

The formulation is used to support fat loss and energy alongside diet and exercise. The evidence is best described component by component: NAD+ precursors such as nicotinamide riboside have been shown in randomized human trials to be well tolerated and to raise NAD+ levels, with some effects on body composition, while the MIC nutrients have defined roles in liver lipid metabolism ^[1][3][4]. As with other lipotropic injections, the specific blend is a compounded product rather than an approved drug with dedicated trials.

This is generally well tolerated, but it is an injectable so sterile technique matters; sloppy handling invites infection or abscesses. You may feel a niacin-style flush, warmth or a metabolic rush from the NAD+ if it goes in fast, so slow it down. Some people get mild nausea, a fishy body odor from choline, or injection-site soreness. Methionine loading can nudge homocysteine up, which is worth knowing if you carry cardiovascular risk. None of this is FDA approved as a weight-loss drug; MIC shots live in the compounding-pharmacy and research space, and quality varies by source. Talk to a doctor if you are pregnant, on methylation-sensitive meds, or have liver or kidney issues.

Lipo-MIC + NAD+ is a modern extension of the classic lipotropic injection, joining the long-established MIC nutrients (methionine, inositol, and choline) with NAD+, the coenzyme central to cellular energy production. The lipotropic MIC concept dates to mid-twentieth-century observations that these methyl-donor nutrients help the liver export fat, while therapeutic interest in NAD+ and its precursors surged much more recently, driven by research into mitochondrial energy and the NAD+-dependent sirtuin enzymes involved in metabolism and aging.

Like other compounded wellness injectables, this blend has no single inventor or defining pivotal trial; it is a clinic-and-pharmacy formulation whose history is the combined history of its ingredients. The novelty lies in pairing traditional lipid support with a foundational energy coenzyme that has become a focus of contemporary metabolic and longevity research. Much of the supporting human evidence for the NAD+ component comes not from NAD+ injections directly but from studies of oral NAD+ precursors such as nicotinamide riboside.

Lipo-MIC + NAD+ carries the appeal of combining a time-tested lipotropic base with one of the most talked-about molecules in modern metabolic and longevity science. The rationale is coherent and honestly stated: the MIC nutrients help the liver package and export fat, while NAD+ fuels the mitochondrial reactions that ultimately burn it and activates sirtuins that regulate fat handling. Interest in NAD+ is well earned, with clinical work on its precursors showing that boosting NAD+ status is feasible and generally well tolerated, and in one randomized trial nicotinamide riboside modestly increased fat-free mass and sleeping metabolic rate.

Candor is warranted, though: those same human studies often found no improvement in insulin sensitivity or other headline metabolic outcomes, and the strongest data come from oral precursors rather than injected NAD+ itself. As a supportive, mechanism-driven adjunct for people pursuing fat loss and vitality, it is a compelling contemporary take on the lipotropic injection, best paired with realistic expectations.